Universitätsklinikum Freiburg

Freiburg im Breisgau, Baden-Wurttemberg 79106

4 studies enrolling now · 15 studies all time

What they study most

Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia, Breast Cancer, Cancer, Carcinoma, Renal Cell, Chronic Myelomonocytic Leukemia, Connective Tissue Disease-Associated Pulmonary Arterial Hypertension, Diabetic Macular Edema, Focal Epilepsy, Low-grade Glioma, Metastatic Castration-Resistant Prostate Cancer, Myelodysplastic Syndrome/Neoplasm

Studies at this site

• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT — Recruiting now
• A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) — Recruiting now
• Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer — Running, not enrolling
• Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy — Running, not enrolling
• DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) — Running, not enrolling
• Long-term Safety and Tolerability of BHV-7000 — Enrolling by invitation
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's — Running, not enrolling
• Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST — Stopped early
• A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) — Stopped early
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) — Completed
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) — Stopped early
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus — Stopped early
• A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC — Stopped early